Theravance Biopharma’s (TBPH) “Buy” Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Theravance Biopharma (NASDAQ:TBPH) in a research note released on Friday,Benzinga reports. They currently have a $21.00 target price on the biopharmaceutical company’s stock.

Several other research firms have also commented on TBPH. HC Wainwright raised their price objective on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Wall Street Zen downgraded Theravance Biopharma from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 3rd. Weiss Ratings reiterated a “hold (c)” rating on shares of Theravance Biopharma in a research note on Thursday, January 22nd. Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. Finally, B. Riley Financial reissued a “neutral” rating and set a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a research report on Wednesday, March 4th. Two equities research analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $22.60.

Theravance Biopharma Trading Up 2.3%

Shares of TBPH stock opened at $14.33 on Friday. The company’s fifty day simple moving average is $18.00 and its 200-day simple moving average is $16.89. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $21.03. The company has a market cap of $726.10 million, a PE ratio of 7.06 and a beta of 0.17.

Theravance Biopharma (NASDAQ:TBPH) last posted its earnings results on Wednesday, March 25th. The biopharmaceutical company reported $1.15 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.71. Theravance Biopharma had a net margin of 98.54% and a return on equity of 18.55%. The business had revenue of $45.89 million for the quarter, compared to analyst estimates of $43.09 million. Equities research analysts expect that Theravance Biopharma will post -1.09 EPS for the current fiscal year.

Insider Activity at Theravance Biopharma

In related news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the transaction, the senior vice president directly owned 232,699 shares in the company, valued at approximately $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 6.90% of the company’s stock.

Institutional Trading of Theravance Biopharma

Several institutional investors and hedge funds have recently bought and sold shares of TBPH. Caitong International Asset Management Co. Ltd lifted its holdings in Theravance Biopharma by 51.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,133 shares of the biopharmaceutical company’s stock worth $77,000 after buying an additional 1,408 shares during the last quarter. Pacer Advisors Inc. bought a new stake in shares of Theravance Biopharma in the 4th quarter valued at approximately $6,342,000. Invesco Ltd. increased its holdings in shares of Theravance Biopharma by 622.2% in the 4th quarter. Invesco Ltd. now owns 177,946 shares of the biopharmaceutical company’s stock valued at $3,329,000 after acquiring an additional 153,306 shares during the last quarter. Mackenzie Financial Corp acquired a new stake in shares of Theravance Biopharma during the 4th quarter valued at approximately $705,000. Finally, Susquehanna Portfolio Strategies LLC raised its position in shares of Theravance Biopharma by 208.8% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 43,350 shares of the biopharmaceutical company’s stock valued at $811,000 after acquiring an additional 29,313 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company’s stock.

More Theravance Biopharma News

Here are the key news stories impacting Theravance Biopharma this week:

• Positive Sentiment: Company highlights and cash/milestone strength — Theravance reported record brand-level profitability for YUPELRI®, received milestone payments tied to sales, expects ~ $400M in cash at end-Q1 2026 with no debt, and announced cost-reduction targets to generate $60–$70M of annualized cash flow starting Q3 2026. Theravance Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Analyst optimism — BTIG reaffirmed a buy rating and set a $21 price target (material upside from current levels), and Zacks upgraded TBPH to a Rank #1 (Strong Buy), supporting the short-term positive sentiment. Benzinga Zacks: Rating Upgrade to Strong Buy
• Neutral Sentiment: Mixed earnings coverage — company releases show strong non‑GAAP profitability and reported milestone-driven revenue, but media/analytics outlets are publishing differing EPS figures (reports vary between a beat and a miss depending on metric/adjustment). Investors should check the company filing for GAAP vs. non‑GAAP reconciliations. Press Release — Q4 and Full Year 2025 Results Zacks: Q4 Earnings and Revenues Lag Estimates
• Negative Sentiment: Pipeline setback and strategic review — management discontinued ampreloxetine after Phase 3 CYPRESS results, is implementing a restructuring, and has formed a Strategic Review Committee to evaluate options including a potential sale — these actions reduce near-term R&D upside and signal material change in corporate strategy. Zacks: Q4 Earnings and Revenues Miss; Ampreloxetine Scrapped
• Negative Sentiment: Insider selling — SVP Rhonda Farnum sold ~31,067 shares in mid‑March; while not definitive, the sale is being watched by investors as a near-term negative signal. InsiderTrades: SVP Sells Shares

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.